Patient adherence, injection prevention, heightened drug production, and self-administration are some of the primary drivers of the estimated 6.4% annual growth of the containers of a unit-dose, and it is expected to hit US$57.9 billion by the end of 2025, according to the new analysis of Freedonia Group.
The blister packaging for solid dose applications will lead the worldwide market. The parenteral vials and pre-fillable syringes will encounter the fastest growth. Enhancing patient compliance through packaging designs is one of the significant trends that support the unit-dose market. This will accelerate the blister and strip pack usage. Clinical drug trials will boost the growth prospects for the unit-dose packaging systems promoting recordkeeping and compliance.
The Freedonia Group analysis predicts that due to the increased need for better infection control systems, the use of pen adaptable cartridges, auto-retractable pre-fillable syringes, and high-barrier parenteral vials would increase throughout the world’s medical community. It is a response to the requirement for improved infection prevention systems.
Blister growth is driven by competition
The intensifying private and generic label competition promotes drug manufacturers to upgrade the containers to influence the medical providers’ and consumers’ purchasing decisions.
According to Freedonia analyst Bill Martineau, the imposed downward pricing pressures by private and public health insurance providers boost the personal and general label competition. Also, because of acquisitions and mergers, the number of proprietary drug distributors and makers is slightly decreasing, and the number of generic distributors and producers is increasing.
Efforts in enhancing the convenience and aesthetic properties of the pharma packaging apply massively to the over-the-counter supplements and drugs sold in retail stores. Also, enhancements in the ethical packaging of the drug include ease of delivery and infection prevention features.
Vaccines and new therapies demand unit-dose syringes
According to the study, biosimilar and new treatments for viral disorders, cancer, and several other debilitating problems will boost the demand for unit-dose parenteral vials and pre-fillable syringes. Martineau says that all these drugs are packaged in unit-dose containers almost always.
Additionally, the current enhancements in syringe safety and design are responsible for the rise in the therapies approved for self-injection. Therefore, it accelerates the demand for unit-dose parenteral vials and pre-fillable syringes. According to Martineau, self-injection therapies are mostly packages in either multi-use devices with cartridges or single-dose syringes.
An increased focus on infection prevention in the delivery system of the parenteral drug in clinics, hospitals, nursing homes, and physicians’ offices also contributes to the rise of unit-dose parenteral vials and syringes.
To conclude, the demand for all these unit-dose formats will rise. It will be the response to the expansion of the worldwide preventive medicine that needs a single-dose injectable vaccine for the diseases like shingles, meningitis, influenza, and Covid-19. The medical sector is making drastic improvements. So, within the coming few years, it will elevate things to a whole new level. With technological advancement and heightened consumer demand, things will get intense very soon.